Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
FY2017 Earnings Roundup - 2: Global Brands Gaining Further Traction, Some Notch Better-than-Expected Growth
By Reiji Anasako While suffering an uphill struggle at home, Japan drug makers enjoy robust revenues from their global brands, with their major products driving their earnings with double-digit growth. They will likely carry on this momentum this fiscal year,…
To read the full story
Related Article
- FY2017 Earnings Roundup - 4: Japan Makers Struggling to Recoup R&D Investments, New Value-Generating Model Is a Must
June 8, 2018
- FY2017 Earnings Roundup - 3: Top 3 Japan Generic Makers Pursuing Diversified Overseas Strategies
June 7, 2018
- FY2017 Earnings Roundup - 1: Major Japan Makers Braced for Gloomier Year Ahead at Home, See 4.4% Dip
June 4, 2018
BUSINESS
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
- GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
- Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…